Assessment of the risk-benefit ratio for antiarrhythmic drug use.

abstract：:Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...

journal_title：Drugs

authors： Bryson HM,Faulds D

更新日期：1997-05-01 00:00:00

abstract：:Alectinib (Alecensa(®)) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan ...

journal_title：Drugs

authors： McKeage K

更新日期：2015-01-01 00:00:00

abstract：:Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...

journal_title：Drugs

authors： Keam SJ

更新日期：2020-01-01 00:00:00

abstract：:Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...

journal_title：Drugs

authors： Triano LR,Deshpande H,Gettinger SN

更新日期：2010-01-01 00:00:00

abstract：:Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding ho...

journal_title：Drugs

authors： Holtzman CW,Brady KA,Yehia BR

更新日期：2015-04-01 00:00:00

abstract：:Developed by Bayer in Germany, nifedipine was shown to be effective in the treatment of patients with angina pectoris by Japanese investigators. Professor Kimura first reported the efficacy of nifedipine in patients with angina pectoris and those findings have been replicated in numerous trials conducted since then. C...

journal_title：Drugs

authors： Hosoda S

更新日期：2006-01-01 00:00:00

abstract：:Bronchial asthma is an inflammatory disease. The characteristic pathological features of epithelial cell loss, goblet cell hyperplasia, increased deposition of collagen beneath the basement membrane, mast cell degranulation, and inflammatory cell infiltration of the mucosa are not limited to fatal asthma. Similar infl...

journal_title：Drugs

authors： Beasley R,Roche W,Holgate ST

更新日期：1989-01-01 00:00:00

abstract：:During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

journal_title：Drugs

authors： Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

更新日期：1998-01-01 00:00:00

abstract：:Hairy cell leukaemia is an uncommon B cell chronic lymphoproliferative disorder characterised by circulating lymphocytes displaying prominent cytoplasmic projections. Therapy is initiated for severe cytopenias or recurrent infections. Splenectomy, the first standard treatment, is now less commonly used as primary trea...

journal_title：Drugs

authors： Gollard R,Lee TC,Piro LD,Saven A

更新日期：1995-06-01 00:00:00

abstract：:The efficacy of an antiretroviral (ARV) treatment regimen depends on the activity of the regimen's individual ARV drugs and the number of HIV-1 mutations required for the development of resistance to each ARV - the genetic barrier to resistance. ARV resistance impairs the response to therapy in patients with transmitt...

journal_title：Drugs

authors： Tang MW,Shafer RW

更新日期：2012-06-18 00:00:00

abstract：:Invasive candidiasis has emerged as an important cause of morbidity and mortality in intensive care unit patients. This short review focuses on many aspects of Candida infection in critically ill patients including epidemiology, impact on mortality, problems related to diagnosis, strategies to identify patients at ris...

journal_title：Drugs

authors： Pennisi M,Antonelli M

更新日期：2009-01-01 00:00:00

abstract：:This article is a review of the principal drug-induced psychiatric symptoms that are likely to be encountered in daily clinical practice as a result of drug abuse, overdoses or side effects of drugs prescribed for treatment. Many categories of medication have the potential to produce psychiatric symptoms, but antitube...

journal_title：Drugs

authors： Johnson DA

更新日期：1981-07-01 00:00:00

abstract：:In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

journal_title：Drugs

authors： Dhillon S

更新日期：2020-06-01 00:00:00

abstract：:Along with nausea and vomiting, postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anaesthesia. The distinguishing factor during electromyogram recordings between patients with postanaesthetic shivering and shivering in fully awake patients is the existence of clo...

journal_title：Drugs

authors： Alfonsi P

更新日期：2001-01-01 00:00:00

abstract：:Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...

journal_title：Drugs

authors： Willkens RF

更新日期：1990-01-01 00:00:00

abstract：:Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...

journal_title：Drugs

authors： Paik J,Deeks ED

更新日期：2019-07-01 00:00:00

abstract：:In a double-blind, crossover study we have investigated the effect of nedocromil sodium on neurokinin A (NKA)-induced bronchoconstriction in asthmatics. 12 patients with mild asthma inhaled either nedocromil sodium 4mg or placebo, on 2 separate days, as 2 puffs from a metered-dose aerosol 30 minutes before challenge w...

journal_title：Drugs

authors： Joos GF,Pauwels RA,Van der Straeten ME

更新日期：1989-01-01 00:00:00

abstract：:Alprazolam is a triazolobenzodiazepine which is related to diazepam and other 1,4-benzodiazepines, and has a similar pharmacological profile. Relative to the newer benzodiazepines, alprazolam has an intermediate half-life of 10 to 12 hours in healthy young subjects. In placebo-controlled and double-blind comparative t...

journal_title：Drugs

authors： Dawson GW,Jue SG,Brogden RN

更新日期：1984-02-01 00:00:00

abstract：:Acarbose delays digestion of complex carbohydrates and disaccharides to absorbable monosaccharides, by reversibly inhibiting alpha-glucosidases within the intestinal brush border, thereby attenuating postprandial blood glucose peaks. Clinical trials have demonstrated that acarbose generally improves glycaemic control ...

journal_title：Drugs

authors： Balfour JA,McTavish D

更新日期：1993-12-01 00:00:00

abstract：:Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. However, the majority of patients with NSCLC will ultimately develop resistance to initial platinu...

journal_title：Drugs

authors： Barnfield PC,Ellis PM

更新日期：2016-09-01 00:00:00

abstract：:Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol...

journal_title：Drugs

authors： Syed YY

更新日期：2018-03-01 00:00:00

abstract：:Acute myocardial infarction (AMI) recognises no boundaries, and the patient's greatest need occurs at the interface between primary care and hospital system. Ideally, the general practitioner, if summoned, should be able to provide resuscitation, analgesia with opiates, and thrombolytic therapy. Thrombolytics should c...

journal_title：Drugs

authors： Rawles J

更新日期：1995-10-01 00:00:00

abstract：:Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

journal_title：Drugs

authors： Markham A,Keam SJ

更新日期：2019-06-01 00:00:00

abstract：:Drotrecogin alfa (activated), recombinant human activated protein C, inhibits coagulation and inflammation and promotes fibrinolysis in patients with severe sepsis. 850 patients with severe sepsis treated with intravenous drotrecogin alfa (activated) 24 microg/kg/h for 96 hours had a significantly greater reduction in...

journal_title：Drugs

authors： Lyseng-Williamson KA,Perry CM

更新日期：2002-01-01 00:00:00

abstract：:Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizu...

journal_title：Drugs

authors： Lyseng-Williamson KA

更新日期：2011-03-05 00:00:00

abstract：:A number of drugs are available that act fairly specifically as "mild" analgesics, although this description by no means implies that their clinical effectiveness is limited to the relief of slight pain and trivial disability. They are effective by mouth and their action is mediated peripherally. Among the possible me...

journal_title：Drugs

authors： Parkhouse J

更新日期：1975-01-01 00:00:00

abstract：:Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid, has a similar pharmacological profile to that of its developmental predecessor gabapentin, but showed greater analgesic activity in rodent models of neuropathic pain. The exact mechanism of action of pregabalin is unclear, a...

journal_title：Drugs

authors： Frampton JE,Scott LJ

更新日期：2004-01-01 00:00:00

abstract：:Drug development offers potential solutions to a number of tropical health diseases, although the expense of pharmaceutical research and lack of return on investment has limited the production of new agents. The greatest successes have been through the development of single dose therapy and mass treatment control prog...

journal_title：Drugs

authors： Stephenson I,Wiselka M

更新日期：2000-11-01 00:00:00

abstract：:The naturally occurring catecholamines, noradrenaline, adrenaline and dopamine, have been found in a wide range of animal and vegetable tissues, but are particularly associated with nervous tissue in animals. Of the many processes affecting the response to stimulation of catecholamine containing nerves, the synthesis ...

journal_title：Drugs

authors： Laverty R

更新日期：1978-11-01 00:00:00

abstract：:Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

journal_title：Drugs

authors： Greig SL

更新日期：2015-09-01 00:00:00